Healthy Clinical Trial
Official title:
Phyllantus Amarus for the Protection of Liver Health: A Randomized, Double Blind, Placebo Controlled Crossover Study
Verified date | November 2017 |
Source | Biotropics Malaysia Berhad |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is a randomized, double-blind, placebo controlled crossover study. The purpose of this study is to assess the ability of Phyllantus amarus to protect the liver against temporary stress including oxidative stress induced by alcohol consumption.
Status | Completed |
Enrollment | 15 |
Est. completion date | October 16, 2010 |
Est. primary completion date | October 16, 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Healthy male or female 21-50 years of age, inclusive. - Subject consumes at least 5 servings of alcohol per week on a regular basis. - Minimum POMS score of 15. - Access to a computer and internet - Subject is willing to maintain his or her habitual food and beverage intake (other than substitution of study food for similar products) and physical activity patterns throughout the study period. - Body mass index (BMI) between 20 and 30 kg/m2. - Subject is willing and able to comply with the alcohol consumption requirements. - Subjects willing to stay in the clinic for two overnight stays - Judged by the Investigator to be in general good health on the basis of medical history. - Subject understands the study procedures and signs forms providing informed consent to participate in the study and authorization for release of relevant protected health information to the study investigator. Exclusion Criteria: - Any Liver condition including Hepatitis, Fatty Liver, Liver Disease. - Liver Function greater than three times the upper level limit of normal - History or record of aggressive or violent behavior - Any significant GI condition that would potentially interfere with the evaluation of the study product [e.g., Ulcerative Colitis or Crohn's Disease, inflammatory bowel disease, irritable bowel syndrome, Clinically significant Gastritis, history of upper GI bleed (bleeding ulcer), chronic constipation (defined as <3 bowel movements per week), history of frequent diarrhea, history of surgery for weight loss, gastroparesis, clinically important lactose intolerance]. - Clinically significant renal, hepatic, endocrine (including diabetes mellitus), cardiac, pulmonary, pancreatic, neurologic, or biliary disorder. - Known allergy or sensitivity to any ingredients in the study products. - Extreme dietary habits (e.g., vegan, Atkins Diet, etc.). - Recent (within two weeks of visit 1, week -1) episode of acute gastrointestinal illness such as nausea, vomiting, or diarrhea. - Uncontrolled hypertension (systolic blood pressure _160 mm Hg or diastolic blood pressure _100 mm Hg at visit 1, week -1). - History or presence of cancer in the prior two years, except for non-melanoma skin cancer. - Any major trauma or surgical event within three months of visit 1, week -1. - Recent use of antibiotics (within 6 weeks). - Females who are pregnant, lactating, planning to be pregnant during the study period. - Recent history of (within 12 months) or strong potential for alcohol or substance abuse. Alcohol abuse will be defined as >14 drinks per week (1 drink =12 ounces beer, 5 ounces wine, or 1 ½ ounces distilled spirits). - Participation in a clinical study with exposure to any non-registered drug product within 30 days prior. - Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk - Current active respiratory illness at the time of screening - Any immune system disorders - Subjects with a history of perforation of the stomach or intestines - Subjects who have had gastric bypass surgery - Untreated Hypothyroidism - Subjects with active eating disorder including anorexia nervosa, bulimia, and/or obsessive compulsive eating disorders - Spinal cord injuries |
Country | Name | City | State |
---|---|---|---|
United States | Medicus Research, LLC | Northridge | California |
Lead Sponsor | Collaborator |
---|---|
Biotropics Malaysia Berhad |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Compare the effect of Phyllantus versus placebo on adverse events | 36 days | ||
Other | Compare the effect of Phyllantus versus placebo on a comprehensive metabolic panel (CMP) analysis | 26 days | ||
Other | Compare the effect of Phyllantus versus placebo on complete blood count | 26 days | ||
Other | Compare the effect of Phyllantus versus placebo on Urinalaysis | 26 days | ||
Primary | Compare the effect of Phyllantus versus placebo on HS CRP levels in blood | 26 days | ||
Primary | Compare the effect of Phyllantus versus placebo on the inflammatory cytokines in blood | 26 days | ||
Primary | Compare the effect of Phyllantus versus placebo on liver function levels in blood | 26 days | ||
Primary | Compare the effect of Phyllantus versus placebo on glutatoine peroxidase (GSH-Px) in blood | 26 days | ||
Secondary | Compare the effect of Phyllantus versus placebo on hangover severity score | 26 days | ||
Secondary | Compare the effect of Phyllantus versus placebo on profile of mood states (POMS) | 26 days | ||
Secondary | Compare the effect of Phyllantus versus placebo on cognitive performance tests | Using the CNS Vital Signs System | 26 days | |
Secondary | Compare the effect of Phyllantus versus placebo on sleep quality | Based on the number of hours slept | 26 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |